PDS Biotechnology Corporation filed a Form 8-K on September 22, 2026, disclosing a press release announcing the publication of Phase 2 trial results for its HPV16-targeted immunotherapy PDS0101 in combination with pembrolizumab in the September 17, 2026, issue of JAMA Oncology.

Key Highlights

  • Publication venue: Results appeared in the September 17, 2026, issue of JAMA Oncology, described in the filing as "a peer reviewed journal of the American Medical Association."
  • Trial name and design: The published article covers the VERSATILE-002 study, a nonrandomized clinical trial evaluating PDS0101 plus pembrolizumab.
  • Patient population: The trial enrolled patients with HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma, according to the filing.
  • Drug combination studied: PDS0101, described as an HPV16-targeted T cell immunotherapy, was evaluated in combination with pembrolizumab.
  • Signed by: The filing was signed by Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotechnology Corporation.

VERSATILE-002 Phase 2 Results Published in Peer-Reviewed Journal

According to the 8-K filed on September 22, 2026, by PDS Biotechnology Corporation (NASDAQ:PDSB), the company issued a press release on the same date announcing that Phase 2 clinical trial data for its candidate PDS0101 had been published in JAMA Oncology. The filing identifies JAMA Oncology as "a peer reviewed journal of the American Medical Association," with the specific issue dated September 17, 2026.

The filing discloses that the published article is titled "VERSATILE-002 - A Phase 2 Study of PDS0101 HPV16-targeted T Cell Immunotherapy and Pembrolizumab Combination in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Nonrandomized Clinical Trial." The study examined PDS0101 in combination with pembrolizumab in a patient population with HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma, as described in the filing.

The 8-K was filed under Item 8.01, designated for Other Events. The full press release dated September 22, 2026, was filed as Exhibit 99.1 and incorporated by reference. The filing does not include clinical outcome data, efficacy figures, or safety results within its body text; those details are contained in the attached press release and the referenced journal publication.

What Was Disclosed

PDS Biotechnology Corporation disclosed via an 8-K that VERSATILE-002 Phase 2 trial results for PDS0101 combined with pembrolizumab in HPV16-positive head and neck cancer were published in JAMA Oncology on September 17, 2026, with a related press release attached as Exhibit 99.1.